Page 138 - 202013

and restores the susceptibility of imipenem against [J]. CPT Pharmacometrics Syst Pharmacol，2019. DOI：
KPC-producing enterobacteriaceae[J]. Antimicrob Agents 10.1002/psp4.12462.
Chemother，2018. DOI：10.1128/AAC.00174-18. [32] RIZK ML，JUMES P，LASSETER K，et al. Pharmacoki-
[26] KANJ SS，KANAFANI ZA. Current concepts in antimi- netics of MK-7655，a novel beta-lactamase inhibitor
crobial therapy against resistant Gram-negative organisms： （BLI），in combination with imipenem/cilastatin （IPM/
extended-spectrum beta-lactamase-producing enterobacte- CIL） in subjects with impaired renal function[EB/OL].
riaceae，carbapenem-resistant enterobacteriaceae，and mul- [2020-05-25]. http：//apps.webofknowledge.com/full_re-
tidrug-resistant pseudomonas aeruginosa[J]. Mayo Clin cord.do?product=UA&search_mode=GeneralSearch&qid=
Proc，2011，86（3）：250-259. 4&SID=8AI5cArUfgIIhXZ7p4L&page=3&doc=26.
[27] JAMES AK，SIBYLLI HL，JANET R，et al. In-vitro activi- [33] WU J，RACINE F，WISMER MK，et al. Exploring the
ty of imipenem/relebactam and key beta-lactam agents pharmacokinetic/pharmacodynamic relationship of rele-
against Gram-negative bacilli isolated from lower respira- bactam（MK-7655）in combination with imipenem in a
tory tract infection samples of intensive care unit patients- hollow-fiber infection model[J]. Antimicrob Agents Che-
SMART Surveillance United States 2015-2017[J]. Int J mother，2018. DOI：10.1128/AAC.02323-17.
Antimicrob Agents，2020. DOI：https：//doi.org/10.1093/ [34] BHAGUNDE P，PATEL P，LALA M，et al. Population
cid/ciaa381. pharmacokinetic analysis for imipenem-relebactam in
[28] JUMES P，RIZK ML，GUYLERREZ M，et al. Phase Ⅰ healthy volunteers and patients with bacterial infections
studies evaluating the safety，tolerability，and pharmacoki- [J]. CPT Pharmacometrics Syst Pharmacol，2019，8（10）：
netics of multiple doses of an intravenous beta-lactamase 748-758.
inhibitor in healthy young males and single doses in [35] LUCASTI C，VASILE L，SANDESC D，et al. Phase 2，
healthy elderly male，elderly female and young female vol- dose-ranging study of relebactam with imipenem-cilas-
unteers[EB/OL].[2020-05-25]. http：//apps.webofknowl- tatin in subjects with complicated intra-abdominal infec-
edge.com/full_record.do?product=UA&search_mode=Ge- tion[J]. Antimicrob Agents Chemother，2016. DOI：10.
neralSearch&qid=2&SID=8AI5cArUfgIIhXZ7p4L&page= 1128/AAC.00633-16.
2&doc=18. [36] SIMS M，MARIYANOVSKI V，MCLEROTH P，et al.
[29] RIZK ML，RHEE EG，JUMES PA，et al. Intrapulmonary Prospective，randomized，double-blind，phase 2 dose-rang-
pharmacokinetics of relebactam，a novel beta-lactamase ing study comparing efficacy and safety of imipenem/
inhibitor，dosed in combination with imipenem-cilastatin cilastatin plus relebactam with imipenem/cilastatin alone
in healthy subjects[J]. Antimicrob Agents Chemother，2018. in patients with complicated urinary tract infections[J]. J
DOI：10.1128/AAC.01411-17. Antimicrob Chemother，2017，72（9）：2616-2626.
[30] RHEE EG，RIZK ML，CALDER N，et al. Pharmacokinet- [37] MOTSCH J，MURTA DE OLIVEIRA C，STUS V，et al.
ics，safety，and tolerability of single and multiple doses of RESTORE-IMI 1：amulticenter，randomized，double-blind
relebactam，a beta-lactamase inhibitor，in combination trial comparing efficacy and safety of imipenem/relebac-
with imipenem and cilastatin in healthy participants[J]. An- tam vs colistin plus imipenem in patients with imipen-
timicrob Agents Chemother，2018. DOI：10.1128/AAC. em-nonsusceptible bacterial infections[J]. Clin Infect Dis，
02197-18. 2020，70（9）：1799-1808.
[31] BHAGUNDE P，PATEL P，LALA M，et al. Population （收稿日期：2020-02-20 修回日期：2020-05-26）
pharmacokinetic analysis for imipenem-relebactam in （编辑：唐晓莲）
healthy volunteers and patients with bacterial infections

《中国药房》杂志——中国科技论文统计源期刊，欢迎投稿、订阅

·1664 · China Pharmacy 2020 Vol. 31 No. 13 中国药房 2020年第31卷第13期